Compare Citius Pharmaceuticals Inc (CTXR) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.35 (market cap $561.25M). The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is far larger — about 41.2× Citius Pharmaceuticals Inc's market cap, and First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| CTXR | QCLN | |
|---|---|---|
Market Cap | $13.62M | $561.25M |
Volume | 132,438 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $68.47 |
52-Week Low | $0.48 | $41.10 |
Typical Hold Time | 17 Days | 50 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
QCLN trades at $48.35, down 2.2% today, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's performance is heavily influenced by U.S. clean energy policy and geopolitical developments, with recent news highlighting global renewable energy acceleration amid tensions. Support and resistance levels cluster around $50-$52, indicating a key price zone for near-term direction.
The outlook for QCLN hinges on political support for clean energy and rising electricity demand, offering growth potential but facing volatility from policy shifts. Risks include regulatory uncertainty and competitive pressures, while analyst sentiment remains watchful amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
